Wainua(Eplontersen)
Acetylcysteine Injection, FLUIMUCIL, Acetylcysteine InjectionAcetylcysteine Injection, FLUIMUCIL, Acetylcysteine InjectionAcetylcysteine Injection, FLUIMUCIL, Acetylcysteine Injection
Reference price:
Manufacturer:
ASTRAZENECA AB
Formulation:
INJECTION
Validity period:
Reminder: The outer packaging is for reference only, please purchase and use under the guidance of a pharmacist. For read by medical and pharmaceutical professionals only.

WAINUA (eplontersen) is a transthyretin-directed antisense oligonucleotide approved for treating polyneuropathy in adults with hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis). By degrading TTR mRNA, it reduces the production of abnormal TTR protein, slowing disease progression.  

Administered monthly via subcutaneous injection, WAINUA requires vitamin A supplementation due to its effect on serum vitamin A levels. Clinical trials demonstrated significant improvements in neuropathy and quality of life compared to placebo. Its safety profile includes manageable adverse effects such as decreased vitamin A and vomiting.

Generic name

Wainua(Eplontersen)
English name
Eplontersen
Alternative Names
Wainua
Drug prices
Indications

WAINUA is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

Therapeutic Target
Transthyretin (TTR) mRNA - causes degradation of mutant and wild-type TTR mRNA through binding to the TTR mRNA, resulting in reduction of serum TTR protein and TTR protein deposits in tissues.
Active Ingredients
Eplontersen sodium (molecular formula: C₂₉₆H₄₁₇N₇₇O₁₅₆P₂₀S₁₃Na₂₀ and molecular weight: 9046.1 daltons)
Dosage form
INJECTION
specifications
45mg/0.8mL*1vial/box
Description
Eplontersen is a transthyretin-directed antisense oligonucleotide (ASO), covalently linked to a ligand containing three N-acetyl galactosamine (GalNAc) residues to enable delivery of the ASO to hepatocytes. Each single-dose autoinjector contains 45 mg eplontersen (equivalent to 47 mg eplontersen sodium) in 0.8 mL of solution. The solution also contains dibasic sodium phosphate, anhydrous (to adjust pH); monobasic sodium phosphate, dihydrate (to adjust pH); sodium chloride (to adjust tonicity); water for injection; and may include hydrochloric acid and/or sodium hydroxide for pH adjustment between 6.9-7.9. Each dose contains 5 mg of sodium and 5 mg of phosphorus.
Dosage and Administration

The recommended dosage is 45 mg administered by subcutaneous injection once monthly. Remove the autoinjector from refrigeration 30 minutes prior to injection to allow warming to room temperature. Administer into the abdomen, upper thigh region, or back of the upper arm (if administered by a healthcare provider or caregiver). For missed doses, administer as soon as possible and resume monthly dosing from the most recent administration date.

RECOMMENDED ARTICLES
RELATED ARTICLES
Contact Medical Consultant
Global Drug Search
Clinical recruitment
overseas medical treatment
Remote consultation
Note: Our medical consultant will contact you as soon as possible. We promise to strictly protect your privacy.
Click to submit medical consultant
Contact Us
Mailbox:Info@Lucius.La
Welcome To Consult
Ucius Pharmaceuticals (Lao) Co.,Ltd All Rights Reserved